Bill · H.R. 3789· House(119-HR-3789)
DTC Act of 2025
- Introduced
- 6/5/2025
- Last activity
- 6/5/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- David Taylor
- Cosponsors
- - 4 - 4
- Introduced
- In Committee
What this bill would do
The Drug-price Transparency for Consumers Act of 2025 aims to amend the Social Security Act to require pricing disclosures in drug advertisements. It mandates that direct-to-consumer advertisements for prescription drugs or biological products include the wholesale acquisition cost. This requirement applies to products for which payment is available under Medicare or Medicaid. An exemption exists for products with a 30-day supply cost of less than $35. The Secretary of Health and Human Services will establish specific regulations regarding how this information is presented. Manufacturers who fail to comply may face civil money penalties.
Yes· 3 of 8
Does this give people more protection from unfair business practices?+7
The bill enhances consumer protection by requiring transparency in the pricing of drugs through advertisements.
Would people over 65 be better off under this?+5
Seniors on Medicare benefit from greater transparency regarding drug costs.
Would retired people be better off under this?+5
Retirees often rely on Medicare and will benefit from knowing drug costs upfront.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Price Transparency: Consumers will see a clear and conspicuous disclosure of the wholesale acquisition cost for a 30-day supply of a drug or biological product in advertisements (Section 3(b)(1)).
-
Informed Decision Making: Greater insight into drug prices can help consumers determine if they can afford a course of therapy before they begin it (Section 2(b)(3)).
-
Cost Comparison and Savings: Providing price information may allow consumers to select lower-cost alternatives, which can help with price shopping and market competition (Section 2(b)(4) and (5)).
-
Better Financial Planning: Learning the wholesale acquisition cost can help consumers better approximate their actual out-of-pocket costs (Section 2(a)(11)).
Potential Negative Impacts for People
- Exemptions for Lower-Cost Drugs: The requirement to disclose pricing does not apply to prescription drugs or biological products where the wholesale acquisition cost for a 30-day supply is less than $35 (Section 3(a)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+5Good For Seniors+5Good For Low Income Households+4Good For Middle Class Households+4
- Economy And Finance
- Improves Consumer Protection+7Reduces Government Spending+5
- Governance And Ideology
- Improves Government Transparency+5
- Healthcare
- Reduces Prescription Drug Costs+5
- 1/13/2026
- 1 Cosponsor added.
- 10/21/2025
- 1 Cosponsor added.
- 10/3/2025
- 1 Cosponsor added.
- 9/30/2025
- 2 Cosponsors added.
- 7/2/2025
- 2 Cosponsors added.
- 6/5/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Nicholas BegichRepublican · Alaska
Robert BresnahanRepublican · Pennsylvania
Ashley HinsonRepublican · Iowa
Eleanor NortonDemocrat · District of Columbia
Zachary NunnRepublican · Iowa
Mike QuigleyDemocrat · Illinois
Janice SchakowskyDemocrat · Illinois
Eugene VindmanDemocrat · Virginia